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Abstract
Background: Interpreting clinical guideline adherence and the appropriateness of medication regimens requires
consideration of individual patient and caregiver factors. Factors leading to initiation of a medication may differ
from those determining continued use. We believe this is the case for systemic steroid therapy in inflammatory
bowel disease (IBD), resulting in a need to apply methods that separately consider factors associated with initiation
and duration of therapy. To evaluate the relationship between patient characteristics and the frequency and duration of
incident steroid use we apply a 2-part hurdle model to Medicare data. We do so in older patients with tumor necrosis
factor antagonist (anti-TNFs) contraindications, as they are of special interest for compliance with Medicare-adopted,
quality metrics calling for anti-TNFs and nonbiologic immune therapies to reduce steroid utilization. Many older patients
have contraindications to anti-TNFs. However, nonbiologics cause adverse events that are concerning in older adults,
limiting their use in this population and increasing reliance on systemic steroids.
Methods: We used a national Medicare sample for 2006–2009 including patients with 12 months or greater of Parts A
and B and 6 months or greater of Part D coverage, IBD confirmed with at least 2 claims for ICD-9CM 555.xx or 556.xx,
anti-TNF contraindications and without contraindications to nonbiologic agents. We applied a negative binomial-logit
hurdle model to examine patient characteristics associated with systemic steroid utilization.
Results: Among the 1,216 IBD patients without baseline steroid use, 21 % used systemic steroids. Odds of receiving
systemic steroids were greater in those younger, rural, and those receiving other agents. Available patient characteristics
failed to predict longer steroid treatment duration.
Conclusions: Our study identified differences in predictors of frequency and duration of medication use and suggests
the utility of two-part models to examine drug utilization patterns. Applying such a model to Medicare data,
we determined that despite medical consensus that systemic steroid use should be minimized, its use was
substantial. Findings indicate anticipated difficulties in implementing recently adopted quality measures to
avoid systemic steroids.
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Background
Beyond occasional ulcerative colitis patients that can be
managed with aminosalicylates, patients with moderate
to severe inflammatory bowel disease (IBD) require the
use of systemic steroids or “steroid-sparing” regimens in-
cluding tumor necrosis factor antagonists (anti-TNFs) or
nonbiologic immunomodulators (nonbiologics [e.g. thio-
purines, methotrexate]) to control their symptoms. [1–3]
However, systemic steroids do not maintain disease
remission, relegating their appropriateness to the induc-
tion of remission [4, 5]. Furthermore, many steroid-
associated adverse events are duration dependent. The
implication of steroid initiation and of their continued
use therefore differ, as may the patient and caregiver
characteristics determining short and long term steroid
management. Identifying these characteristics is import-
ant, though direct drug costs of systemic steroids are
minimal, the health burden is considerable. Approxi-
mately 10 % of all reported drug adverse events in the
US are associated with systemic steroids according to
Healthcare Cost and Utilization Project (HCUP) analyses
[6]. Such complications are particularly costly in older
patients who are at greater baseline risk [6–8].
Steroid-sparing regimens are associated with deep,
sustained remission and improved health outcomes as
supported by clinical, endoscopic and biomarker evi-
dence [1, 9, 10]. However, they may be expensive and
these medications also have adverse events such as in-
fections and malignancies [1, 9–14]. Considering the
risks and benefits associated with IBD drugs [15], the
Center for Medicare and Medicaid Services (CMS), the
administrator for Medicare, a universal health insurance
program for US citizens ≥65, adopted IBD-specific qual-
ity measures that call for the use of steroid-sparing
maintenance regimens [16]. Specifically, steroid use for ≥
60 days or disease that requires multiple steroid courses
should result in the initiation of steroid-sparing agents
[5, 15, 16]. However, the limited data available suggest
low utilization rates for anti-TNFs and nonbiologic im-
munomodulators compared to high steroid use (9.5 % vs
31 %) in older patients [17].
The low frequency of anti-TNF utilization, and,
thereby, greater use of systemic steroids, may be partly
attributable to higher rates of anti-TNF contraindica-
tions (decompensated congestive heart failure (CHF),
malignancies) in older patients compared to their youn-
ger counterparts [18, 19]. For such patients, nonbiolo-
gics remain a guideline-recommended steroid-sparing
option. Still systemic steroids may be preferred over
nonbiologics by patients and providers. Understanding
drug selection patterns for patients with anti-TNF con-
traindications is critical in light of the new quality meas-
ure, but no information has been published on this
population.
In this paper we examine IBD drug utilization, and pa-
tient characteristics associated with steroid initiation and
the duration of steroid use in a nationally representative
sample of older patients with anti-TNF contraindications,
but without nonbiologic contraindications (hematologic
malignancies, liver disease). We conducted the steroid
analysis using an approach that is underutilized in the
medical literature, the negative binomial logit hurdle
model. We performed this evaluation using data from the
period between the release of the medical position state-
ment [15] supporting the new measure and its adoption
by CMS [16] so that our findings may serve as a baseline
snapshot for future examination of the impact of this na-
tional policy change. While logistic regression has been
used to identify patient characteristics associated with the
frequency of systemic steroid utilization in multiple scler-
osis patients [20], to our knowledge a two-part model has
not previously been used to examine the association be-
tween patient characteristics and the frequency and dur-
ation of incident steroid use. However, using less
frequently deployed analytic methods to examine medica-
tion use is important to determining the value of these
models for such purposes.
Methods
Study Sample
We examined claims and enrollment data for Medicare
fee-for-service (FFS) beneficiaries, which represent ap-
proximately 88 % of all Medicare recipients, to identify a
sample of older adults with a diagnosis of IBD and contra-
indications to anti-TNF therapy [21]. Patients ≥65 years
old with at least 12 months of Parts A and B (hospital and
medical visit) and 6 months of Part D (outpatient pre-
scription) coverage during the years 2006–2009 were in-
cluded. Data were included for up to 6 months prior to
coverage by Medicare D. IBD diagnosis was ascertained
using a case-finding algorithm (≥2 claims for appropriate
International Classification of Diseases, 9th edition (ICD-
9) codes [Crohn’s Disease: 555.xx] or [Ulcerative Colitis:
556.xx]) [22, 23]. The first 12 months of data are referred
to as collected during the “baseline year” and began after
the patient had at least one IBD claim. Data collected after
the baseline period was considered from the “follow-up
period”. Follow-up continued until December 31, 2009,
disenrollment from Medicare Parts A, B or D or death,
whichever occurred first. Patients were excluded if they
did not have a confirmatory IBD claim by the end of the
follow-up period. Drug contraindications were determined
during the baseline year. Contraindication to anti-TNF
therapy was defined as advanced CHF or malignancy. Ad-
vanced CHF was identified as ≥1 outpatient claim for a
CHF diagnosis (ICD-9 398.91, 402.01, 402.11, 402.91,
404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 414.8,
428.x) and at least 1 CHF hospitalization (primary
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inpatient discharge diagnosis code for CHF [ICD-9 codes:
398.91, 404.x1, 404.x3, 428.0–428.9]) [24]. Both solid tumor
and hematologic malignancies were ascertained using the
2008 Elixhauser criteria, version 3.3 (ICD-9 codes: 140.0–
172.9, 174.0–175.9, 179–195.8, 258.01–258.03, 196.0–199.1,
789.51, 200.00–202.38, 202.50–203.01, 203.8–203.81, 238.6,
273.3) [25]. Patients with nonbiologic contraindications
comprising hematologic malignancies (defined above) and
liver disease (ICD-9 codes for 571.0–571.9, 070.2–070.9,
572.2–572.4) [26] were excluded from study as they were
not eligible to receive any steroid- sparing agent.
Outcome Drug Class Variables
The primary outcome variables were receipt and dur-
ation of systemic steroid therapy (prednisone, methyl-
prednisolone, budesonide). Although the entire class of
agents were included as an outcome variable, prednisone
represented >95 % of all incident steroid use in this
study. Systemic steroid use was identified from Medicare
Part D [27] claims history during the time the patient
had Part D coverage, by National Drug Codes (NDCs)
using information on NDCs and therapeutic class in the
Multum Lexicon™ Plus database (Cerner Multum Incor-
porated, Denver, Colorado). A patient day dataset was
constructed with patients assigned to having received
therapy on a given day based upon the ReComp algo-
rithm [28]. Identifying drug administration days allowed
computing period prevalence, treatment duration and
incident drug use.
Incident steroid use was defined as a new claim for
systemic steroids that started during the follow-up
period, and steroid therapy days included all the days
systemic steroids were received (regardless of gaps in
treatment) during the follow-up. Prevalent systemic ster-
oid use is included in the descriptive analysis only.
Explanatory Drug Class Variables
The use of home administered anti-TNF infusions
(infliximab), anti-TNF injections (adalimumab), non-
biologic immunomodulators, aminosalicylates, locally
administered steroids and antidiarrheal therapies were
also identified from Medicare Part D [27] claims history
during the baseline period by the approach used for the
systemic steroid outcome variable. Facility-administered
anti-TNF infusions (infliximab) were ascertained from
Part A and B claims for Healthcare Common Procedure
Coding System (HCPCS) J-code 1745 [27, 29]. These
therapies were assessed during the baseline period and
included as predictors in the model for steroid use.
Other Explanatory Variables
Demographic information was obtained from the Medicare
denominator file. This file was used to determine Medicaid
coverage status. The sample of Medicare beneficiaries was
merged with Census 2010 Summary File 3 (SF3) data
(yielding socioeconomic characteristics on households). Pa-
tient zip-codes were used to assign urban status based on
rural urban commuting area (RUCA) codes [30].
Patient medical and health care characteristics were
ascertained from the Medicare data during the baseline
period, and included a comorbidity index (Charlson index),
IBD disease severity (endoscopies, surgeries), and health re-
source utilization (managing provider type, hospitalization,
emergency department visit).
The primary provider type (primary care provider,
gastroenterologist or other specialists) for IBD manage-
ment was assigned as the provider with the greatest num-
ber of evaluation and management (E&M) IBD visits
(Appendix 1) [31]. Assuming patients may receive one sur-
veillance endoscopy annually [32, 33], we considered >1
endoscopy (identified on outpatient and inpatient claims as
ICD-9 codes and on carrier claims as CPTcodes, Appendix
1) [22] an indicator of disease severity. IBD surgeries were
identified from inpatient claims for an appropriate ICD-9
procedure code (Appendix 1) [34]. Other health resource
use (hospitalizations, emergency department visits), and
comorbidity indices were determined from ICD-9 codes
and HCPCS codes from inpatient claims, carrier claims
and E&M visits, as appropriate [35].
Statistical Analysis
We provide descriptive information on all drug classes
considered and model the use of incident steroid use. Pa-
tients who received systemic steroid therapy during the
baseline period were excluded from regression analyses.
Since the deployment of any systemic steroids is im-
portant and the duration of steroid therapy is separately
an important indicator of appropriate use, we employ a
hurdle model in the analysis of incident steroid use [36].
The logistic portion of the model evaluated patient fac-
tors associated with being an incident steroid recipient.
Furthermore, it is likely that individuals vary in their
propensity to continue on systemic steroids due to un-
measured factors, thereby generating overdispersion and
making the negative binomial a more appropriate choice
for length of steroid treatment than the Poisson. The
negative binomial portion was truncated at zero and
assessed factors associated with steroid therapy days
among incident steroid users.
Robust standard errors were used for statistical infer-
ence on regression coefficients. Because of the relatively
small sample size, forward step-wise model building was
employed for the hurdle model components with socio-
demographic characteristics and IBD drug classes in the
first 12 months included in the initial model and each
candidate covariate of reasonable cell size (>10) considered.
Candidate covariates with descriptive importance (eg. re-
gion) and/or marginal statistical significance (p < 0.1) were
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retained in the final models. Model fit for the logistic part
of the model was evaluated by comparing deciles of ob-
served and predicted percentage receiving systemic ste-
roids using the Hosmer-Lemeshow goodness of fit
statistics (p = ns). Fit of the expected number of observa-
tions from a negative binomial to the data is presented
graphically (Figure 1, Chi square p = ns).
This study included a dynamic cohort with varying
patient follow-up times allowing some participant’s
greater time to receive systemic steroids and add-
itional steroid therapy days; therefore, time-offsets
were used in all models. The logistic time offset was
defined as the natural log of the time from the begin-
ning of the entire observation period until systemic
steroids were initiated for steroid recipients or until
the end of follow-up for non-recipients. For the count
model, the time offset was the time from the begin-
ning of the entire observation period until the end of
follow-up for a given patient. Our time off-set mirrors
the hurdle model weighting approach used by Senturk
and colleagues in their examination of cardiovascular
events in the dialysis population [37].
The results of the hurdle model were compared to
those of fitting a Poisson model with the log link and ro-
bust standard errors to the total number of days on sys-
temic steroids, which is the model frequently used in
medical literature [38]. The same covariates were in-
cluded in the Poisson and hurdle models and signifi-
cance levels compared. We evaluated the Poisson model
fit using the Schwartz Bayesian information criterion
and the degree of over-dispersion using deviance/df.
Since the complementary log-log (CLL) link better cor-
responds to a binary analysis in which time is a consider-
ation in the probability of event occurrence, a sensitivity
analysis of the logistic component of the hurdle model
was performed using the CLL link for the generalized
linear regression of incident steroid utilization, and
generated similar findings (not reported).
Statistical analysis was conducted using Stata version
13 (StataCorp, College Station, TX) and results are pre-
sented as odds ratios (OR), ratio of durations (count
model), and 95 % Confidence Intervals (CI).
This retrospective cohort study was determined to be
exempt from oversight by the University of Wisconsin
Institutional Review Board.
Results
Descriptive Characteristics of Full Study Sample
Eighteen percent (n = 1,860) of the full cohort of
Medicare FFS beneficiaries aged 65+ with IBD (n =
10,362) had anti-TNF contraindications. Of these,
9.6 % (n = 178) also had nonbiologic contraindica-
tions, resulting in a final study sample of 1,682. Over-
all, participants had a mean age of 79 years (sd = 7.7),
68 % were female, 88 % white and 76 % resided in an
urban or suburban area (Table 1). Aminosalicylates,
locally administered steroids and antidiarrheals were
used by 22 %, 1 % and 12 % of study participants at
baseline, respectively. Forty-three percent of partici-
pants (n = 726) received systemic steroid therapy after
starting the study. There were 466 baseline users and
260 incident users who were the focus of the regression
analysis whereas only 5 % (n = 85) received nonbiologic
immunomodulators, and 2 % received anti-TNF therapy
despite having anti-TNF contraindications.
Systemic steroids were the most frequently used
class of agents during every year of observation
(Table 2). The number of patients treated with non-
biologic immunomodulators was substantially smaller
than that of steroid recipients 35–45 users per 1000
patients per year versus 303–345 per 1000 patients
per year, respectively. There were more patients tak-
ing systemic steroids than nonbiologics, but the aver-
age number of days on therapy was shorter for
steroid recipients (124–147 days per year) than for
patients receiving nonbiologics (199–271 days per
year). This is expected given induction steroid therapy
practices that call for shorter treatment courses
(Figure 2).
Multivariable Analyses of Predictors of Incident Steroid
Exposure by 2-part Hurdle Model
A total of 1,216 IBD patients who had no steroid use
during the baseline period were included in the
follow-up analysis. Overall 21 % (n = 260) of steroid
recipients in the regression analysis cohort were inci-
dent users. Patients had greater odds of receiving in-
cident systemic steroids if they were younger (OR =
1.25 per 5 year age decrease, CI = 1.14, 1.39) or lived in
rural areas (OR = 1.54, CI = 1.10, 2.13) (Table 3). Steroid
use was positively and significantly associated with receipt
Fig. 1 Data Fit for Count Model. The average total number of days
of steroid therapy (observed) among patients who received steroid
therapy and the average total number of steroid therapy days that
steroid recipients were expected to receive drug therapy based on
their characteristics
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Table 1 Baseline Participant Characteristics, Overall and by Drug Therapy
Full cohort (n = 1682) Ever systemic steroid users (n = 726)a Ever nonbiologic users (n = 85)a
Sociodemographicsb n % n % n %
Age Mean (SD)c 79 (8) 78 (7)e 75 (7)e
Female 1136 68 494 68 50 59
Caucasian 1474 88 654 90d 80 94
Region
Northeast 444 26 182 25 19 22
Southeast 459 27 208 29 24 28
Midwest 417 25 189 26 28 33
Rocky Mountain 34 2 12 2 <11g <11g
Southwest 163 10 96 10 <11g <11g
Pacific (incl HI, AK, PR)h 165 10 68 9 <11g <11g
Urban/Suburban 1266 76 516 72e 61 72
Medicaid coverage 547 33 219 30 21 25
Clinicalb n % n % n %
Polypharmacy (>5 drugs) 1290 81 602 85e 69 83
Charlson Index Mean (SD) 4 (3) 4 (3) 4 (2)
Primary managing provider type
Primary Care Provider 769 46 320 44.4 38 44.7
Gastroenterologist 19 1 <11g <11g <11g <11g
Other specialists 868 52 393 55 44 52
antiTNF 37 2 26 4e 18 21e
Aminosalicylates 374 22 215 30e 38 45e
Locally administered steroids 12 1 <11g <11d,g <11g <11g
Antidiarrheals 209 12 111 15e 14 17
>1 endoscopy 452 27 201 28 25 29
IBD surgery 106 6 41 6 <11g <11g
Hospitalizations Mean (SD) 2 (2) 2 (2)e 2 (2)
ED visits Mean (SD) 1 (2) 1 (2)e 1 (2)
aBivariate analyses is the comparison of Steroid Use to NonUse; Nonbiologic Use to Nonuse; bBaseline characteristics were ascertained during 12 months prior to
study inclusion; cSD = standard deviation dp < .05, ep < .01, fp < .001; gCell sizes are too small to include variable in regression model & requires cell suppression
hHI = Hawaii, AK = Alaska, PR = Puerto Rico
Table 2 Annual Utilization by IBD Drug Class
Number of utilizers per 1000 IBD patients per yeara
Class of Agent 2006 2007 2008 2009
Systemic Steroids 303 345 336 317
Immunomodulators 48 53 50 45
antiTNFs 12 16 22 17
Nonbiologic Immunomodulatorsb 42 45 37 35
Aminosalicylates 285 265 246 249
Locally administered steroids 12 11 <11c <11c
Antidiarrheals 129 121 115 118
aMid-year population used to calculate utilizers per year
bNonbiologic immunomodulators include azathioprine, mercaptopurine, and methotrexate
cCell size too small and requires suppression
dThese utilization numbers were derived by dividing the number of patients who received a particular drug class during the year by the mid-year study population
and multiplying by 1000.
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Fig. 2 Mean Annual Number of Days on Therapy Among Utilizers. For each year of the study, the number of days that all nonbiologic and systemic
steroid therapy recipients received the respective drug therapy
Table 3 Multivariable Regression Model of Steroid Exposure
Steroid use (yes/no)a Duration of steroid use among utilizersb
OR CI Ratio of Durationsc CI
Age ( 5 year decrease) 1.25 (1.14, 1.39)f 0.97 (0.88, 1.06)
Female 1.30 (0.93, 1.80) 1.11 (0.85, 1.45)
Caucasian 1.46 (0.87, 2.46) 0.87 (0.54, 1.38)
Region
Midwest 1.00 Reference 1.00 Reference
Northeast 0.92 (0.61, 1.37) 1.13 (0.81, 1.57)
Southeast 0.91 (0.61, 1.35) 0.93 (0.67, 1.29)
Southwest 0.80 (0.47, 1.38) 0.84 (0.54, 1.32)
Rocky Mountain 0.44 (0.12, 1.55) 0.90 (0.29, 2.73)
Pacific & HI, AK, PRg 0.70 (0.38, 1.30) 0.84 (0.51, 1.40)
Rural 1.54 (1.10, 2.13)d 0.93 (0.71, 1.20)
Medicaid eligible 0.80 (0.57, 1.13) 0.89 (0.66, 1.20)
antiTNFs 1.66 (0.52, 5.34) 0.63 (0.30, 1.29)
Nonbiologic immunomodulators 2.14 (0.82, 5.57) 0.76 (0.42, 1.36)
Aminosalicylates 1.78 (1.26, 2.51)e 1.01 (0.77, 1.33)
Locally administered steroids 3.77 (0.69, 20.6) 1.41 (0.46, 4.35)
Antidiarrheals 1.72 (1.12, 2.62)d 0.83 (0.59, 1.18)
Charlson index 0.96 (0.90, 1.01) 1.00 (0.95, 1.06)
Hospitalizations 0.97 (0.88, 1.07) 0.99 (0.90, 1.09)
Endoscopy (>1) 1.09 (0.76, 1.56) 0.83 (0.60, 1.15)
IBD-associated Surgery 0.75 (0.40, 1.39) 0.89 (0.48, 1.64)
aDependent variable was incident steroid use during the follow-up period, Individuals with baseline steroid use were excluded from this model (n = 1216)
bDependent variable was days of steroid use among steroid users (n = 260) during the follow-up period, Individuals with baseline steroid use were excluded from
this model; count truncated at zero; cEffect measure is ratio of steroid therapy durations; All explanatory variables are measured within the first 12 months after
study entry; dp < .05, ep < .01, fp < .001; gHI = Hawaii, AK = Alaska, PR = Puerto Rico
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of aminosalicylates and antidiarrheal therapies in the first
12 months.
Longer steroid treatment courses were not associated
with any of the observed patient characteristics (Table 3).
Multivariable Analyses of Predictors of Incident Steroid
Exposure by Simple Model
When predictors of steroid therapy duration are examined
using the simple Poisson regression (Table 4), it is shown
that those who are younger receive additional steroid days
at a greater rate (RR = 1.19 per 5 year lower age, CI = 1.08,
1.31. Poisson regression demonstrated greater rates of add-
itional days of steroid use among locally administered ster-
oid recipients (RR = 4.39, CI = 1.51, 12.70). The Poisson
model, similar to the hurdle model, would have detected
the statistically significant inverse relationship between age
and steroid use (Table 4) but would have failed to identify
rurality and the baseline use of aminosalicylates or antidiar-
rheals as predictors of steroid use.
Discussion
Almost half of the patients in our study received sys-
temic steroids which is greater than expected given that
guidelines advocate systemic steroids be reserved for in-
duction therapy and caution against numerous steroid-
associated adverse events.
The American Gastroenterological Association (AGA)
position underlying the CMS, steroid-sparing quality
metric, states that patients receiving ≥ 60 consecutive days
of systemic steroids should be initiated on an anti-TNF or
nonbiologic unless they have contraindications to those
agents [16]. The patients in our study had contraindica-
tions to anti-TNF therapy; but were eligible for treatment
with nonbiologics. Our findings demonstrate average an-
nual systemic steroid therapy days that are at least double
this recommendation, suggesting significant gaps and con-
flict with the treatment guidelines [16]. The prolonged
steroid treatment courses suggest that steroids are fre-
quently used beyond induction. Specifically, these patients
are at greater risk for the steroid-associated adverse events
seen with longer treatment courses, including hypothal-
amus pituitary adrenal axis suppression, osteoporotic frac-
tures, coronary artery disease, lipodystrophy, cataracts and
potentially serious infections [4, 6]. We found greater initi-
ation of systemic steroids in rural than in urban patients,
reflecting a potential disparity.
The use of nonbiologics instead of systemic steroids is
an innovation, and innovations are more likely to diffuse
and be adopted in cosmopolitan settings with greater
interpersonal communication between providers and
near peer IBD experts [39]. Additionally, patients who
reside in larger, more urban communities may have
greater access to support groups and information motiv-
ating them to request or agree to nonbiologic immuno-
modulators [39].
Two-part models such as hurdle models are rarely re-
ported in the medical literature but common in economics.
The lack of their use may hamper a comprehensive under-
standing of the utilization and predictors associated with
specific drug therapy regimens. The hurdle model fits the
subject matter of steroid use especially well. Importantly re-
ceiving any systemic steroids is typically related to the need
to abate a disease flare after patients have failed less aggres-
sive drugs (aminosalicylates, locally administered steroids
and antidiarrheal therapies) or in settings where newer
therapies are not in common use (rural settings). Prolonged
use may be related to factors that are more difficult to
measure like clinical inertia, patient and clinician prefer-
ences, and suboptimal maintenance regimens.
In the current study, we indeed found that these models
were not overlapping. This is notable because while none
Table 4 Simple Poisson Multivariable Regression Model of
Steroid Exposure
Poisson regression
Duration of Steroid Use
RR CI
Age ( 5 year decrease) 1.19 (1.08, 1.31)e
Female 1.40 (0.97, 2.02)
Caucasian 1.39 (0.80, 2.42)
Region
Midwest 1.00 Reference
Northeast 0.86 (0.56, 1.32)
Southeast 0.71 (0.46, 1.08)
Southwest 0.60 (0.30, 1.18)
Rocky Mountain 0.42 (0.09, 2.05)
Pacific & HI, AK, Prf 0.60 (0.29, 1.23)
Rural 1.23 (0.86, 1.77)
Medicaid eligible 1.04 (0.72, 1.51)
antiTNFs 0.62 (0.19, 2.03)
Nonbiologic immunomodulators 1.58 (0.75, 3.33)
Aminosalicylates 1.41 (0.98, 2.03)
Locally administered steroids 4.39 (1.51, 12.70)d
Antidiarrheals 1.07 (0.69, 1.65)
Charlson index 0.96 (0.90, 1.01)
Hospitalizations 0.96 (0.87, 1.05)
Endoscopy (>1) 0.87 (0.60, 1.27)
IBD-associated Surgery 0.68 (0.35, 1.33)
aDependent variable was days of steroid use among participants (n = 1216)
during the follow-up period; The models were run with robust standard errors,
Individuals with baseline steroid use were excluded from these models; bRR = rate
ratios; All explanatory variables are measured within the first 12 months after study
entry; cp< .05, dp < .01, ep< .001; fHI = Hawaii, AK = Alaska, PR = Puerto Rico
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of the studied characteristics were predictive of pro-
longed use, several factors like being younger and fail-
ing weaker drugs predicted steroid initiation which
underscores the fact that these two relationships
should be modelled separately. The difference was not
due to lack of power in the duration model, as confi-
dence intervals were of similar width, and several of
the non-significant rate ratios were in the opposite
direction from the odds ratios for steroid initiation.
Fitting the simple count model would have incorrectly
concluded that there is no difference between steroid
use in rural versus urban dwellers or for those with
several classes of baseline drug use.
It should be noted that a simple Poisson model
does not separate predictors of initiation and duration
of steroids, as non-use as an outcome is on a con-
tinuum of shorter use. While older age was a pre-
dictor of steroid initiation, it was not related to
duration of use. The Poisson model, while finding age
a significant predictor of duration from zero days on-
wards, does not make that distinction.
Grootendorst showed the utility of a two-part hur-
dle model for a similar application to examine the
effect on prescription drug utilization of removing
prescription copays for individuals’ ≥ 65 years old [40].
In that examination, Grootendorst compared the 2-
part model to simple models. He found the former to
be superior based upon accuracy and model selection
criteria. Grootendorst’s work is relevant to the current
study because we also sought to evaluate drug
utilization and also identified differences between
modeling the simple and 2-part models.
The major strengths of our study were our analytic
approach and the use of a large national sample
allowing us to consider a sub-population of older IBD
patients with anti-TNF contraindications to identify
drug treatment patterns. Reporting on the use of a 2-
part model to examine medication use patterns en-
courage debate regarding the value of these methods
to study complicated utilization patterns. Since we
used CMS’ random sample of Medicare beneficiaries
we were able to include 1,682 older patients with IBD
and anti-TNF contraindications, which allowed us to
examine drug utilization in an un-studied age group
to establish baseline data to evaluate national policy
change. The major limitation to our study was the in-
ability to link steroid use to an indication due to our
use of claims data instead of electronic health re-
cords. Additionally, we cannot tell if nonbiologics
were unsuccessfully tried prior to our investigation
and contributed to low use during our study. How-
ever, even if patients tried nonbiologics in the past,
new data about optimizing nonbiologic regimens may
mean these patients were candidates for renewed
treatment with nonbiologics during our study period
[41, 42].
Conclusion
Our results indicate the importance of separately con-
sidering drug initiation and length of treatment in
identifying determinants of use. Systemic steroids
were overutilized, and our model identifies rural resi-
dence and the baseline use of drug therapies to abate
symptoms as risk factors for steroid initiation. How-
ever, the use of steroids for long treatment courses
represents a quality gap and, potentially, a cost con-
cern given the expense of steroid-associated adverse
events and poorly controlled IBD. Our model showed
that factors associated with initiation did not predict
prolonged steroid use, and identifies this as an area
requiring a dataset with more patient specific vari-
ables. Two part hurdle models are underutilized for
examining duration of therapy in the medical litera-
ture but proved to be useful in our consideration of
steroid therapy predictors. These models may have
wider application to other medication utilization stud-
ies in the future.
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